Merck KGaA said on Tuesday that Allan Gabor will succeed Alasdair Jelfs as managing director for the company in China as of Feb. 1, 2018.
The German company said Mr. Gabor would also take over operational responsibility for the performance materials business in China.
Additionally, Mr. Gabor will become a permanent member of the performance materials leadership team, Merck KGaA said.
Mr. Jelfs take up duties at company headquarters in Darmstadt, Germany, the company said.
Mr. Gabor joined Merck KGaA in 2013, and is currently head of the biopharma business in Asia, including China. Prior to joining the company, Mr. Gabor was head of Pfizer in China.
By Marc Navarro Gonzalez
Source: Dow Jones Newswires via Fox Business
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
